Solvonis Therapeutics Announces Strategic Rebranding, Awakn Acquisition, and 2024 Financial Results
Explore Solvonis Therapeutics' strategic rebrand, Awakn acquisition, and 2024 financial results as the UK biotech targets mental health innovation amid clinical trial risks and funding needs.
April 16, 2025